# Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB01L1 in Healthy Volunteers

> **NCT00724997** · PHASE1 · COMPLETED · sponsor: **AVIR Green Hills Biotechnology AG** · enrollment: 48 (actual)

## Conditions studied

- Seasonal Human Influenza

## Interventions

- **BIOLOGICAL:** GHB01L1

## Key facts

- **NCT ID:** NCT00724997
- **Lead sponsor:** AVIR Green Hills Biotechnology AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2008-07
- **Final completion:** 2008-08
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2009-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00724997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00724997, "Randomized, Double-blind, Placebo-controlled, Phase I Dose-escalation Study of Single Dose GHB01L1 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00724997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*